

AĞRILI HASTAYA YAKLAŞIM

Yazar

Dr. Aynur YURTSEVEN

Editör

Prof. Dr. Umut Yücel Çavuş



© Copyright 2025

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ye aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçla kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

**Bu Kitap, Prof. Dr. Umut Yücel Çavuş'un danışmanlığında yürütülen Dr. Aynur YURTSEVEN'e ait "Acil Servise Ağrı Şikâyeti İle Başvuran Hastalara Verilen Tedavi Etkinliğinin ve Hasta Memnuniyetinin Araştırılması" adlı tezinden üretilmiştir.*

ISBN 978-625-375-591-1	Yayın Koordinatörü Yasin DİLMEN
Kitap Adı Ağrılı Hastaya Yaklaşım	Sayfa ve Kapak Tasarımı Akademisyen Dizgi Ünitesi
Editör Prof. Dr. Umut Yücel Çavuş ORCID iD: 0000-0001-7100-1164	Yayıncı Sertifika No 47518
Yazar Dr. Aynur YURTSEVEN ORCID iD: 0000-0002-1554-0873	Baskı ve Cilt Vadi Matbaacılık
	Bisac Code MED022090
	DOI 10.37609/akya.3765

Kütüphane Kimlik Kartı
Yurtseven, Aynur.

Ağrılı Hastaya Yaklaşım / Aynur Yurtseven; ed. Umut Yücel Çavuş.
Ankara : Akademisyen Yayınevi Kitabevi, 2025.
80 s. : tablo. ; 135x210 mm.
Kaynakça var.
ISBN 9786253755911

UYARI

Bu üründe yer alan bilgiler sadece lisanslı tıbbi çalışanlar için kaynak olarak sunulmuştur. Herhangi bir konuda profesyonel tıbbi danışmanlık veya tıbbi tanı amacıyla kullanılmamalıdır. Akademisyen Kitabevi ve bağlı şirketleri, yazarları, katılımcıları, partnerleri ve sponsorları ürün bilgilerine dayalı olarak yapılan bütün uygulamalardan doğan, insanlarda ve hayvanlarda yaralanma ve/veya hasarlardan sorumlu değildir. İlaçların veya başka kimyasalların reçete edildiği durumlarda, tavsiye edilen dozunu, ilacın uygulanacak süresi, yöntemi ve kontraendikasyonlarını belirlemek için, okuyucuya üretici tarafından her ilaca dair sunulan güncel ürün bilgisini kontrol etmesi tavsiye edilmektedir. Dozun ve hasta için en uygun tedavinin belirlenmesi, tedavi eden hekimin hastaya dair bilgi ve tecrübelerine dayanak oluşturması, hekimin kendi sorumluluğundadır. Akademisyen Kitabevi, üçüncü bir taraf tarafından yapılan ürüne dair değişiklikler, tekrar paketlemeler ve özelleştirmelerden sorumlu değildir.

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A
Yenişehir / Ankara
Tel: 0312 431 16 33
siparis@akademisyen.com

www.akademisyen.com

ÖNSÖZ

Bu eserde, acil servislerde ağrılı hastaya yaklaşımı, verilen tedavi etkinliğini ve hasta memnuniyeti araştıran bir tez çalışmasının sonuçları esas alınarak genel olarak ağrının özelliğinden, ağrılı hastaya yaklaşımda kullanılabilir metodlar ve tedavide kullanılabilir ağrı kesici ajanlardan bahsedilmiştir. Ağrılı hasta yaklaşımında günlük pratikte bu eserin katkı sunacağını umuyorum.

Bu çalışmanın hayata geçirilmesi sürecinde bilgi ve tecrübelerinden faydalandığım Prof. Dr. Umut YÜCEL ÇAVUŞ başta olmak üzere, araştırmamın her bir aşamasında desteklerini sunan değerli arkadaşlarıma ve desteklerini hiçbir zaman eksik etmeyen, her zaman yanımda olan sevgili AİLEME sonsuz teşekkür ediyorum.

Ayrıca bu eserin oluşturulma aşamasında katkı ve desteği olan herkese minnettarım.

Aynur YURTSEVEN

Ankara-2025

İÇİNDEKİLER

BÖLÜM 1

GİRİŞ VE AMAÇ	1
Ağrı	5
Ağrının Sınıflandırılması.....	5

BÖLÜM 2

GENEL BİLGİLER	5
Patofizyolojik Mekanizmalara Göre	6
Süreye Göre	7
Kaynaklandığı Bölgeye Göre	8
Ağrının Nöroanatomi ve Nörofizyolojisi.....	9
Nosisseptör ve Çevresi	10
Nosisseptif Çıkıcı Sistemler	10
Antinosiseptif İnici Sistemler	11
Persepsiyon	12
Ağrının Değerlendirilmesi ve Kullanılan Ölçekler	13
Sayısal Derecelendirme Ağrı Ölçeği.....	13
Wong-Baker FACES Ağrı Ölçeği	13
FLACC Ağrı Ölçeği.....	14
CRIES Ağrı Ölçeği	14
COMFORT Ölçeği.....	15
McGill Ağrı Anketi	16
Renkli Analog Skala.....	17
Kısa Ağrı Envanteri (BPI).....	17
Analjeziklerin Temel Sınıflandırılması.....	18
Steroid Olmayan Antiinflatuar İlaçlar	19
Non Steroidal Antiinflatuar İlaçların Sınıflandırılması.....	21

İçindekiler

Salisilatlar	23
Parasetamol (Asetaminofen)	24
Pirazolon Türevleri	25
Fenilpropiyonik Asit Türevleri	25
Fenilasetik Asit Türevleri	26
İndolasetik Asit Türevleri	27
COX-2 Selektif İnhibitörleri	27
Opioid Analjezikler.....	28
Opioidlerin Olumsuz Etkileri.....	30
Tolerans ve Bağımlılık Patofizyolojisi	32
Morfin	34
Remifentanil	35
Meperidin.....	35
Fentanil.....	36
Metadon	37
Diğer Opioid Analjezikler.....	37
Opioid Antagonistleri	37
Hasta Seçimi.....	39
BÖLÜM 3	
MATERYAL VE METOD.....	39
Verilerin İstatistiksel Analizi	40
BÖLÜM 4	
BULGULAR.....	43
BÖLÜM 5	
TARTIŞMA	57
BÖLÜM 6	
SONUÇ.....	63
KAYNAKLAR	64

KISALTMALAR

- ASA** : Asetilsalisilik asit
ACh : Asetilkolin
ACTH : Adrenokortikotropik hormon
ADH : Antidiüretik hormon
BPI : Brief Pain Inventory (Kısa Ağrı Envanteri)
cAMP : Siklik Adenozin Monofosfat
CO₂ : Karbondioksit
Cl⁻ : Klorür
COX : Siklooksijenaz
COX-1 : Siklooksijenaz-1
COX-2 : Siklooksijenaz-2
DOR : Delta reseptörü
GİS : Gastrointestinal sistem
GnRH : Gonadotropin salgılatıcı hormon
HHA : Hipotalamus-hipofiz-adrenal
IASP : International Association for the Study of Pain
(Uluslararası Ağrı Araştırmaları Derneği)
IV : İntravenöz
İM : İntramüsküler
KOR : Kappa reseptörü
LC : Locus ceruleus
MOR : mü reseptörü
M3G : Morfin-3-glukuronid
M6G : Morfin-6-glukuronid

Kısaltmalar

- NOR** : Nosisepsiyon reseptörü
NSAİİ : Non steroid antienflamatuar ilaç
NRS : Numeric Rating Scale (Sayısal Derecelendirme Skalası)
NK : Doğal öldürücü
NE : Norepinefrin
NOWS : Neonatal opioid yoksunluk sendromu
NO : Nitrik oksit
OİBD : Opioid kaynaklı bağırsak disfonksiyonu
PDMP : Prescription Drug Monitoring Programs
(Reçeteli İlaç İzleme Programları)
PG : Prostaglandin
PGG : Prostaglandin G
PGH : Prostaglandin H
PGI₂ : Prostatiklin
PPI : Proton Pompası İnhibitörü
REM : Rapid Eye Movement (Hızlı Göz Hareketi)
SIADH : Uygunsuz ADH Salgılanma Sendromu
TXA₂ : Tromboksan A₂
VPL : Ventral posterolateral
YBÜ : Yoğun Bakım Ünitesi
ZOR : Zeta reseptörü
4-MAA : 4-metilamino antipirin

KAYNAKLAR

1. Raja, S. N., Carr, D. B., Cohen, M., et al. (2020). The revised International Association for the Study of Pain definition of pain: Concepts, challenges, and compromises. *Pain*, 161(9), 1976–1982. <https://doi.org/10.1097/j.pain.0000000000001939>
2. Jensen, T. S., & Gebhart, G. F. (2008). New pain terminology: A work in progress. *Pain*, 140(3), 399–400.
3. Raj, P. P. (2000). Ağrı Toxonomisi: Ağrı. In S. Erdine (Ed.), *Ağrı*. İstanbul: Nobel Tıp Kitabevi.
4. Lui, L. Y., So, W. K., & Fong, D. Y. (2008). Knowledge and attitudes regarding pain management among nurses in Hong Kong medical units. *Journal of Clinical Nursing*, 17(15), 2014–2021.
5. Eti Aslan F. Ache epidemiology. In: Eti Aslan F, editor. Ache nature and control. 2nd ed. Ankara. Academician Bookstore; 2014.
6. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*, 390(10100), 1211–1259. [https://doi.org/10.1016/S0140-6736\(17\)32154-2](https://doi.org/10.1016/S0140-6736(17)32154-2).
7. Andrews, J. S., Cenzer, I. S., Yelin, E., et al. (2013). Pain as a risk factor for disability or death. *Journal of the American Geriatrics Society*, 61(4), 583–589. <https://doi.org/10.1111/jgs.12163>.
8. Gerdle, B., Björk, J., Henriksson, C., et al. (2004). Prevalence of current and chronic pain and their influences upon work and healthcare-seeking: A population study. *Journal of Rheumatology*, 31(7), 1399–1406.
9. İlaç Endüstrisi İşverenleri Sendikası (İEİS). (2001). *Endüstrinin 2000 yılı verileri*. İEİS Aylık Rapor, 20(1), 20–21.
10. Chou, R., Gordon, D. B., de Leon-Casasola, et al. (2016). Management of postoperative pain: A clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *The Journal of Pain*, 17(2), 131–157. <https://doi.org/10.1016/j.jpain.2015.12.008>.
11. Rupp, T., & Delaney, K. A. (2004). Inadequate analgesia in emergency medicine. *Annals of Emergency Medicine*, 43(4), 494–503.
12. Yılmaz, F., & Atay, S. (2014). Hemşirelik öğrencilerinin klinik ağrı yönetimi. *Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi*, 1(2), 32–41.
13. Orr, P. M., Shank, B. C., & Black, A. C. (2017). The role of pain classification systems in pain management. *Critical Care Nursing Clinics of North America*, 29(3), 407–418. <https://doi.org/10.1016/j.ccell.2017.05.002>.
14. Bonezzi, C., Fornasari, D., Cricelli, C., et al. (2020). Not all pain is created equal: Basic definitions and diagnostic work-up. *Pain and Therapy*, 9(Suppl 1), 1-15. <https://doi.org/10.1007/s40122-020-00217-w>.

15. International Association for the Study of Pain (IASP). (2021). *Terminology*. <https://www.iasp-pain.org/resources/terminology/#pain>.
16. Morgan, G. E., & Mikhail, M. G. (1996). Pain management. In *Clinical anesthesiology* (2nd ed., pp. 274–316). New Jersey: Prentice Hall International, Inc.
17. Kosek, E., Cohen, M., Baron, R., et al. (2016). Do we need a third mechanistic descriptor for chronic pain states? *Pain: The Journal of the International Association for the Study of Pain*, 157(7), 1382-1386. <https://doi.org/10.1097/j.pain.0000000000000507>.
18. Ingram SL. Molecular Basis of Nociception. Youmans and Winn Neurological Surgery, 167, e605-e612. Copyright © 2017 by Elsevier, Inc.
19. Treede, R., Rief, W., Barke, A., et al. (2019). Chronic pain as a symptom or a disease: The IASP classification of chronic pain for the International Classification of Disease (ICD-11). *Pain: The Journal of the International Association for the Study of Pain*, 160(1), 19–27. <https://doi.org/10.1097/j.pain.0000000000001384>.
20. Stubhaug, A. (2005). Can opioids prevent post-operative chronic pain? *European Journal of Pain*, 9(2), 153–156. <https://doi.org/10.1016/j.ejpain.2004.07.007>
21. Murphy, P. (2007). Somatic pain. In R. Schmidt & W. Willis (Eds.), *Encyclopedia of Pain* (pp. 2190–2191). Heidelberg, Germany: Springer.
22. Loeser, J. D., Butler, S. H., Chapman, C. R., et al. (2001). General considerations of chronic pain. In J. D. Loeser, S. H. Butler, C. R. Chapman, & D. C. Turk (Eds.), *Bonica's Management of Pain* (3rd ed., pp. 241–254). Lippincott Williams & Wilkins.
23. Martin TJ, Ewan E. Chronic pain alters drug self-administration: implications for addiction and pain mechanisms. *Exp Clin Psychopharmacol*. 2008;16: 357-66.
24. Milligan, E. D., & Watkins, L. R. (2009). Pathological and protective roles of glia in chronic pain. *Nature Reviews Neuroscience*, 10(1), 23–36. <https://doi.org/10.1038/nrn2533>.
25. Heavner JE, Willis WD. Pain pathways: Anatomy and physiology. In: Raj PP (ed). *Practical Management of Pain*, 3 ed. St Louis: Mosby Inc., 2000; 107-45
26. Sorkin, L. S. (1997). Basic pharmacology and physiology of acute pain processing. In M. S. Wallace, J. S. Dunn, & T. L. Yaksh (Eds.), *Anesthesiology Clinics of North America* (pp. 235–250). Philadelphia, PA: W.B. Saunders Company.
27. Hirshberg, R. M., Al-Chaer, E. D., Lawand, N. B., et al. (1996). Is there a pathway in the posterior funiculus that signals visceral pain? *Pain*, 67(2-3), 291–305. [https://doi.org/10.1016/0304-3959\(96\)03127-2](https://doi.org/10.1016/0304-3959(96)03127-2).
28. Yegül İ, Ağrı ve Tedavisi. İstanbul, Yapım matbaacılık, 1993; 1-27.
29. Gutstein, H. B., & Akil, H. (2006). Opioid analgesics. In L. L. Brunton (Ed.), *Goodman and Gilman's the pharmacological basis of therapeutics* (11th ed., pp. 547–590). McGraw-Hill.

30. Woolf, C. J., Cheong, M. S., et al. (1993). Preemptive analgesia treating postoperative pain by preventing the establishment of central sensitization. *Anesthesia & Analgesia*, 77(2), 362–363.
31. Aslan, F. E. (2002). Ağrı değerlendirme yöntemleri. *Cumhuriyet Üniversitesi Hemşirelik Yüksekokulu Dergisi*, 6(1), 9–16.
32. Van Dijk, F. M. J., Kappen, H. T., van Wijk, A. J. M., et al. (2012). The diagnostic value of the numeric pain rating scale in older postoperative patients. *Journal of Clinical Nursing*, 21(19-20), 3018–3024. <https://doi.org/10.1111/j.1365-2702.2012.04288.x>
33. Hawker, A. G., Mian, S., Kendzerska, T., et al. (2011). Measures of adult pain. *Arthritis Care & Research*, 63(11), 240–252. <https://doi.org/10.1002/acr.20543>
34. Jastrzab, G., Kerr, S., & Fairbrother, G. (2009). Misinterpretation of the Face Pain Scale-Revised in adult clinical practice. *Acute Pain*, 11(2), 51–55. <https://doi.org/10.1177/174501790901100206>.
35. Crellin, D. J., Harrison, D., Santamaria, N., et al. (2018). Psychometric properties of the FLACC scale used to assess procedural pain. *The Journal of Pain*, 19(8), 862–872. <https://doi.org/10.1016/j.jpain.2018.02.013>
36. Krechel, S. W., & Bildner, J. (1995). CRIES: A new neonatal postoperative pain measurement score. Initial validation. *Pain*, 61(1), 13–20. [https://doi.org/10.1016/0304-3959\(94\)00191-v](https://doi.org/10.1016/0304-3959(94)00191-v)
37. Boerlage, A. A., Ista, E., Duivenvoorden, H. J., et al. (2015). The COMFORT behavior scale detects clinically significant effects of analgesic and sedative treatment. *European Journal of Pain*, 19(4), 473–479. <https://doi.org/10.1002/ejp.569>.
38. Bourdel, N., Alves, J., Pickering, G., et al. (2015). Systematic review of endometriosis pain assessment: How to choose a scale? *Human Reproduction Update*, 21(1), 136–152. <https://doi.org/10.1093/humupd/dmu046>.
39. Le May, S., Ballard, A., Khadra, C., et al. (2018). Comparison of the psychometric properties of 3 pain scales used in the pediatric emergency department: Visual Analog Scale, Faces Pain Scale-Revised, and Color Analog Scale. *Pain*, 159(8), 1508–1517. <https://doi.org/10.1097/j.pain.0000000000001236>.
40. Lin, C., & Poquet, N. (2016). Brief Pain Inventory. *Journal of Physiotherapy*, 62(52). <https://doi.org/10.1016/j.jphys.2015.07.001>.
41. Melli, M., & Kayaalp, S. O. (2005). Non-steroidal antiinflatuar ilaçlar. In S. O. Kayaalp (Ed.), *Rasyonel Tedavi Yönünden Tıbbi Farmakoloji* (1st ed., pp. 837–870). Ankara: Hacettepe-Taş.
42. World Health Organization. (1996). *Cancer pain relief: With a guide to opioid availability* (2nd ed.). Geneva: WHO.
43. Vadivelu, N., Mitra, S., & Narayan, D. (2011). Recent advances in postoperative pain management. *Yale Journal of Biology and Medicine*, 83(1), 11–25.

44. Simon, L. S. (2013). Nonsteroidal anti-inflammatory drugs and their risks: A story still in development. *Arthritis Research & Therapy*, 15(Suppl 3), S1. <https://doi.org/10.1186/ar4173>.
45. Dubois, R. N., Abramson, S. B., Crofford, G., et al. (1998). Cyclooxygenase in biology and disease. *FASEB Journal*, 12(13), 1063–1073. <https://doi.org/10.1096/fasebj.12.13.1063>
46. Kawai, S., Shinichi, N., Kato, M., et al. (1998). Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. *European Journal of Pharmacology*, 347(1), 87–94. [https://doi.org/10.1016/S0014-2999\(98\)00347-2](https://doi.org/10.1016/S0014-2999(98)00347-2)
47. Ghosh, R., Alajbegovic, A., & Gomes, A. V. (2015). NSAIDs and cardiovascular diseases: The role of reactive oxygen species. *Oxidative Medicine and Cellular Longevity*, 2015, Article ID 536962. <https://doi.org/10.1155/2015/536962>.
48. Fenner H: Differentiating among nonsteroidal antiinflammatory drugs by pharmacodynamic profiles, *Arthritis Rheum*, 1997 26(1); 28–33.
49. Süleyman, H., Demircan, B., & Karagöz, Y. (2007). Anti-inflammatory and side effects of cyclooxygenase inhibitors. *Pharmacological Reports*, 59, 247–258.
50. Ruiz, J. G., & Lowenthal, D. T. (1997). NSAIDs and nephrotoxicity in the elderly. *Geriatrics Nephrology and Urology*, 7, 51–57.
51. Basivireddy J, Jacob M, Pulimood AB, et l. Indomethacin-induced renal damage: role of oxygen free radicals. *Biochem Pharmacol*. 2004;67: 587-99.
52. Bort, R., Ponsoda, X., Jover, R., et al. (1999). Diclofenac toxicity to hepatocytes: A role for drug metabolism in cell toxicity. *Journal of Pharmacology and Experimental Therapeutics*, 288(1), 65–72.
53. Pinsky, P. F., Hurwitz, E. S., Schonberger, L. B., et al. (1988). Reye's syndrome and aspirin. Evidence for a dose-response effect. *JAMA*, 260(5), 657–661. <https://doi.org/10.1001/jama.1988.03410050065030>
54. Henry, D. (1990). Assessing the benefits and risks of drugs: The example of NSAIDs. *Australian Family Physician*, 19(6), 378–383.
55. Vane, J. R., & Botting, R. M.(2003). The mechanism of action of aspirin. *ThrombosisResearch*, 110(5–6), 255–258. [https://doi.org/10.1016/S0049-3848\(03\)00379-7](https://doi.org/10.1016/S0049-3848(03)00379-7)
56. Patrono, C., García Rodríguez, L. A., Landolfi, R., et al. (2001). Low-dose aspirin for the prevention of atherothrombosis. *New England Journal of Medicine*, 353(22), 2373–2383. <https://doi.org/10.1056/NEJMra052717>
57. Flower, R. J. (2013). *Anti-inflammatory drugs and their mechanism of action*. In: *Pharmacology of Inflammation* (Elsevier).
58. Lehman, J.W., *Operational Organich Chemistry*, 4th ed., New Jersey, Prentice Hall, 2009
59. Kayaalp SO . Nonsteroidal antiinflamatuvar ilaçlar. Kayaalp O (editör). *Rasyonel Tedavi Yönünden Tıbbi Farmakoloji*. 9. Baskı. Ankara: Hacettepe Taş Yayınları, 2000: 1026-62.

60. Kayaalp SO. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. Hacettepe-Taş Kitapçılık Ltd Şti, 2005:945-960
61. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. *Arch Intern Med* 2000; 160:777-84.
62. Scarpignato, C., Lanas, A., Blandizzi, C., et al., & International NSAID Consensus Group. (2015). Safe prescribing of nonsteroidal anti-inflammatory drugs in patients with osteoarthritis: An expert consensus addressing GI and cardiovascular risks as well as benefits. *BMC Medicine*, 13, 55. <https://doi.org/10.1186/s12916-015-0285-8>.
63. Hodgman MJ, Garrard AR. (2012). A review of acetaminophen poisoning. *Critical Care Clinics* 28:499-516.
64. Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. *Proceedings of the National Academy of Sciences of the United States of America*, 99(21), 13926-13931. <https://doi.org/10.1073/pnas.212471299>
65. Gallego-Sandín, S., Novalbos, J., Rosado, A., et al. (2004). Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: Correlation with endoscopic lesions and adverse reactions. *Digestive Diseases and Sciences*, 49(9), 1538-1544. <https://doi.org/10.1023/B:DDAS.0000049281.61429.c1>.
66. Van Hecken A, Schwartz JI, Depré M i wsp. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. *J Clin Pharmacol* 2000; 40: 1109-1120.
67. Brutzkus JC, Shahrokhi M, Varacallo M. Naproxen. W: StatPearls. Treasure Island (FL). StatPearls Publishing, 2020.
68. Andreassen, K. H., Eldrup, J., Hansen, R. I., & Oster, S. (1999). Tiaprofenic acid-induced cystitis—Three cases and a literature review. *Scandinavian Journal of Urology and Nephrology*, 33(4), 408-410. <https://doi.org/10.1080/00365599950166156>
69. Burke, A., Smyth, E., & FitzGerald, G. A., 2006. Analgesic antipyretic agents; pharmacotherapy of gout. In brunton LL, ed. Goodman&camp; Gilman's the pharmacological basis of therapeutics. USA, The McGraw-Hill Companies; 695-96.
70. Simmons DL, Wagner D, Westover K. Non-steroidal anti-inflammatory drugs, acetaminophen, cyclooxygenase 2, and fever. *Clin Infect Dis* 2000; 31(Suppl 5): S211-8.
71. Risser A, Donovan D, Heintzman J, Page T. NSAID prescribing precautions. *Am Fam Physician* 2009; 80: 1371- 8.
72. Zarghi, A., & Arfaei, S. (2011). Selective COX-2 inhibitors: Investigation of structure-activity relationships. *Iranian Journal of Pharmaceutical Research*, 10(4), 655-683.

73. Lau, L., Hansford, L. M., Cheng, L. S., et al. (2007). Cyclooxygenase inhibitors regulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. *Oncogene*, 26(13), 1920–1931. <https://doi.org/10.1038/sj.onc.1209981>
74. Toubia, T., & Khalife, T. (2019). The endogenous opioid system: Role and dysfunction caused by opioid therapy. *Clinical Obstetrics and Gynecology*, 62(1), 3–10. <https://doi.org/10.1097/GRF.0000000000000419>
75. Centers for Disease Control and Prevention (CDC). (2016). *Injury prevention and control: Opioid overdose*. Retrieved September 15, 2016, from <http://www.cdc.gov/drugoverdose/index.html>
76. Corder, G., Castro, D. C., Bruchas, M. R., et al. (2018). Endogenous and exogenous opioids in pain. *Annual Review of Neuroscience*, 41, 453–473. <https://doi.org/10.1146/annurev-neuro-080317-061522>.
77. Pathan, H., & Williams, J. (2012). Basic opioid pharmacology: An update. *British Journal of Pain*, 6(1), 11–16. <https://doi.org/10.1177/2049463712438493>.
78. Zöllner, C., & Stein, C. (2007). Opioidler. In *Handbook of Experimental Pharmacology* (Vol. 177, pp. 31–63). https://doi.org/10.1007/978-3-540-33823-9_2
79. Cohen B, Ruth LJ, Preuss CV. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): April 29, 2023. Opioid Analgesics.
80. James, M. K., Feldmann, P. L., Schuster, S. V., et al. (1991). Opioid receptor activity of GI87084B, a novel ultra-short acting analgesic, in isolated tissues. *Journal of Pharmacology and Experimental Therapeutics*, 259(2), 712–718.
81. Galligan, J. J., & Akbarali, H. I. (2014). Molecular physiology of enteric opioid receptors. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 307(6), G507-G516. <https://doi.org/10.1152/ajpgi.00187.2014>
82. Yuan, C. S., Wang, C. Z., & Yang, Y. C (2017). Opioids and opioid antagonists: gastrointestinal effects and clinical utility. *Current Gastroenterology Reports*, 19(5), 22. <https://doi.org/10.1007/s11894-017-0561-1>.
83. Tyan, P., & Carey, E. T. (2019). Physiological response to opioids. *Clinical Obstetrics and Gynecology*, 62(1), 11–21.
84. Karahan, S., Karagöz, H., Erden, A., et al. (2014). Codeine-induced syndrome of inappropriate antidiuretic hormone: Case report. *Balkan Medical Journal*, 31(1), 107–109. <https://doi.org/10.5152/balkanmedj.2014.13109>
85. Al-Hasani, R., & Bruchas, M. R. (2011). Molecular mechanisms of opioid receptor-dependent signaling and behavior. *Anesthesiology*, 115(6), 1363–1381.
86. Murdoch, J., Crooks, A., & Miller, D. (2002). Effect of the addition of ketamine to morphine in patient-controlled analgesia. *Anaesthesia*, 57(5), 484–490.
87. Slover RB, Phelps RW. Opioid and non opioid analgesics. In: Brown DL. Regional anesthesia and analgesia 2. edition, Philadelphia- Pennsylvania: Mao foundation 1996; 319- 356.

88. Joshi GP, Jamerson BD, Roizen MF, et al. Is there a learning curve associated with the use of remifentanyl? *Anesth Analg* 2000; 91: 1049- 1055.
89. Richard F. Clark, Edward M. Wei , Philip O. Anderson Meperidine: Therapeutic use and toxicity. *The Journal of Emergency Medicine*, Volume 13, Issue 6, November–December 1995, Pages 797-802.
90. Glick JL, Christensen T, Park JN, et al. Stakeholder perspectives on implementing fentanyl drug checking: Results from a multi-site study. *Drug Alcohol Depend*. 2019 Jan 01;194:527-532.
91. Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. *Neurosci Biobehav Rev*. 2019 Nov;106:49-57.
92. Gallagher R. Opioid-Related Harms: Simplistic Solutions to the Crisis Ineffective and Cause Collateral Damage. *Health Serv Insights*. 2018;11:1178632918813321.
93. Morbidity and Mortality Weekly Report (MMWR). (2016). Contextual evidence review for CDC guideline on opioid prescribing for chronic pain—United States, 2016. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports; volume 65, no. RR-1.
94. Oktay C. Girişimsel Sedasyon ve Analjezi. II. Acil Tıp Sempozyumu Kitapçığı, İzmir, 1999, s:123-145.
95. Nicolaou DD. Systemic Analgesia and Sedation for Painful Procedures. In Tintinalli JE, Kelen GD, Stapczynski JS (eds): *Emergency Medicine A Comprehensive Study Guide*. 5th ed. New York: The Mc Graw Hill Companies, 2000, pp:269-274.
96. Substance Abuse and Mental Health Services Administration (SAMHSA). (2016). *Buprenorphine*. <https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine>
97. Ducharme J. Acute pain management. In: Tintinalli JE, Stapczynski JS, Ma OJ, Yealy DM, Meckler GD, Cline DM, editors. *Tintinalli's Emergency Medicine: A Comprehensive Study Guide*. 9th ed. New York, NY: McGraw Hill Education; 2019. p. 229-36.
98. Selbst SM, Clark M. Analgesic use in the emergency department. *Ann Emerg Med* 1990; 19:1010-3.
99. Todd KH, Samaroo N, Hoffman JR. Ethnicity as a risk factor for inadequate emergency department analgesia. *JAMA* 1993;269:1537-9.
100. Todd KH, Deaton C, D'Adamo AP, et al. Ethnicity and analgesic practice. *Ann Emerg Med* 2000;35: 11-6.
101. Nelson BP, Cohen D, Lander O, et al. Mandated pain scales improve frequency of ED analgesic administration. *Am J Emerg Med* 2004;22:582-5.
102. Safdar B, Heins A, Homel P, et al. Impact of physician and patient gender on pain management in the emergency department – A multicenter study. *Pain Med* 2009;10:364-72.
103. Ducharme J, Barber C. A prospective blinded study on emergency pain assessment and therapy. *J Emerg Med* 1995;13: 571-5.

104. Allione A, Melchio R, Martini G, et al.(2011). Factors influencing desired and received analgesia in emergency department *J Pain* 8(6):460–466 *Intern Emerg Med* 6:69–78.
105. Singer A, J, Garra G, Chohan J K, et al. Triage Pain Scores and the Desire for and Use of Analgesics. *Annals of Emergency Medicine* Volume52 no:6: December -2008.
106. Todd HK, Ducharme J, Choiniere M, et al, for the PEMI Study Group Pain in the emergency department: results of the pain and emergency medicine initiative (PEMI) multicenter study. *The Journal of Pain*, Vol 8, No 6 (June), 2007: pp 460-466.
107. Çetin, M., Kaya, B., Yılmaz Kılıç, T., et al. (2021). Pain management practices in the emergency departments in Turkey. *Turkish Journal of Emergency Medicine*, 21(4), 189–197. <https://doi.org/10.4103/2452-2473.329633>.
108. Todd HK, Sloan EP, Chen C, et al.(2002). Survey of pain etiology, management practices and patient satisfaction in two urban emergency departments *Em Advances • Innovations En Mu juillet CJEM*; Jul;4(4):252-6. doi: 10.1017/s1481803500007478..
109. Bijur PE, Latimer CT, Gallagher EJ.(2003). Validation of a verbally administered numerical rating scale of acute pain for use in the emergency department. *Acad Emerg Med* 10: 390-392.
110. Guru V, Dubinsky I.(2000). The patient vs. caregiver perception of acute pain in the emergency department. *J Emerg Med* ;18: 7-12.